Glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST segment elevation myocardial infarction

Coronary Artery Disease

Volumn 10, Issue 8, 1999, Pages 561-566

  Cannon, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

IIb IIIa inhibition; Myocardial infarction; Platelet inhibitors; Unstable angina

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; TIROFIBAN;

ANGINA PECTORIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG MECHANISM; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; ST SEGMENT ELEVATION; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0032795154     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199912000-00004     Document Type: Review

References (20)

1. 1 Cannon CP, Braunwald E. The spectrum of myocardial ischemia: the paradigm of acute coronary syndromes. In: Cannon CP, editor. Management of acute coronary syndromes. Totowa: Humana Press; 1999. pp. 3-18.
2. 2 Braunwald E, Mark DB, Jones RH, Cheitlin MD, Fuster V, McCauley KM, et al. Unstable angina: diagnosis and management. Clinical practice guideline Number 10. Rockville, MD: Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, US Department of Health and Human Services; 1994. p. 154.
3. 3 The Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338:1488-1497.
4. 4 The Platelet Receptor Inhibition For Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338:1498-1505.
5. 5 The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patient with acute coronary syndromes. N Engl J Med 1998; 339:436-443.
6. 6 Peterson JG, Lauer MA, Sapp SK, Topol EJ. Heparin use is required for clinicial benefit of GP IIb/IIIa inhibitor eptifibatide in acute coronary syndromes: insights from the PURSUIT trial [abstract]. Circulation 1998; 98 (suppl I):I-360.
7. 7 The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349:1429-1435.
8. 8 Theroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquid J-F, et al. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. Circulation 1996; 94:899-905.
9. 9 The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin or both in unstable angina. Circulation 1998; 97:2386-2395.
10. 10 Topol EJ. Toward a new frontier in myocardial reperfusion therapy. Emerging platelet preeminence. Circulation 1998; 97:211-218.
11. 11 Sax FL, Watson AS, Zhao X-Q, Snapinn SM, Barr E, Theroux P. Correlation between ischemic cardiac events and presence of intracoronary thrombus in acute coronary syndrome patients [abstract]. Circulation 1998; 98 (suppl I):I-492.
12. 12 TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) Trial; Phase I findings. N Engl J Med 1985; 312:932-936.
13. 13 Zhao X-Q, Deckelbaum LI, Barr E, Snapinn SM, Shaw WC, Sax FL, et al. Impaired coronary perfusion is associatd with worse clinical outcomes in unstable angina/non-Q wave myocardial infarction patients [abstract]. Circulation 1998; 98 (suppl I):I-359.
14. 14 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk angioplasty. N Engl J Med 1994; 330:956-61.
15. 15 The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336:1689-1696.
16. 16 The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess the safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352:87-92.
17. 17 The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997; 349:1422-1428.
18. 18 The RESTORE Investigators. The effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96:1445-1453.
19. 19 Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, et al. A randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial. Circulation 1998; 97:340-349.
20. 20 Mark DB, Talley JD, Topol EJ, Bowman L, Lam LC, Anderson KM, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation 1996; 94:629-635.